Welcome to our dedicated page for Genetron Holdings news (Ticker: GTH), a resource for investors and traders seeking the latest updates and insights on Genetron Holdings stock.
Genetron Holdings Limited (NASDAQ: GTH) is a leading precision oncology platform company based in China. With a focus on cancer molecular profiling, Genetron leverages advanced technologies in molecular biology and data science to revolutionize cancer treatment.
The company's extensive portfolio spans various stages of cancer management, including early screening, diagnosis, treatment recommendations, and continuous monitoring. Some of its flagship services and products include:
- HCCscreen: A proprietary assay for the early detection of liver cancer.
- 8-gene Lung Cancer Assay: An in-vitro diagnostic tool based on semiconductor sequencing for lung cancer detection.
- Genetron 3D Biochip Reading Instrument and Genetron S5 and S2000: Advanced sequencers for gene detection and panel sequencing.
- IDH1/TERT Gene Assays: Diagnostic assays for glioma.
In addition, Genetron has developed a ctDNA Lung Cancer Assay targeting mutations in the epidermal growth factor receptor gene. The company collaborates with global biopharmaceutical firms to offer tailored genomics research and clinical development services.
Recently, Genetron announced a definitive Agreement and Plan of Merger with New Genetron Holding Limited and Genetron New Co Limited. As part of the merger, Genetron will become a wholly-owned subsidiary of the parent company in a transaction valued at approximately US$126.0 million. This merger signifies a pivotal transformation, taking the company private and enhancing its strategic flexibility.
The merger completion, expected in the first quarter of 2024, is subject to customary closing conditions, including shareholder votes and regulatory approvals. Upon completion, Genetron's American Depositary Shares (ADSs) will be delisted from the Nasdaq Global Market, and the company will terminate its ADS program. The company aims to finalise this transition efficiently to focus on its long-term vision and goals.
For the latest updates and detailed information on Genetron Holdings Limited and its innovative contributions to precision oncology, please visit their Investor Relations page.
Genetron Holdings Limited (NASDAQ: GTH) announced a collaboration with AstraZeneca R&D China to create next-generation sequencing-based minimal residual disease (MRD) tests for solid tumors in China. This multi-year agreement will see both companies jointly invest and develop personalized MRD assays for cancer monitoring. AstraZeneca will integrate these tests into specific studies. Genetron's proprietary Mutation Capsule technology will aid in detecting genetic alterations using smaller blood samples, enabling significant cost and time savings in diagnostics.
Genetron Holdings Limited (NASDAQ: GTH) disclosed two significant research findings at the Association for Molecular Pathology 2021 annual meeting. The studies validated the effectiveness of its Seq-MRD® product in detecting minimal residual disease in B-lymphoid malignancies and FusionScan Plus for identifying numerous gene mutations and fusions concurrently. Both products demonstrated high sensitivity and specificity, enhancing clinical diagnosis and treatment strategies. An exclusive agreement with Jiangsu Fosun Pharma aims to expedite Seq-MRD®'s adoption in key Chinese hematology facilities.
Genetron Holdings Limited (Nasdaq: GTH), a leading precision oncology platform in China, will participate in the 8th BioCentury-BayHelix China Healthcare Summit from November 16-19, 2021. CFO Evan Xu will discuss capital markets in China and the U.S. during a panel, focusing on regulatory risks and investor expectations. Genetron Health specializes in molecular profiling tests and cancer management, offering comprehensive services from early screening to continuous monitoring. For more information, visit Genetron Health's website.
Genetron Holdings Limited (NASDAQ: GTH) has announced the publication of a new computational method showcasing the UVC algorithm’s performance in enhancing the variant calling process in next-generation sequencing (NGS). Published in Briefings in Bioinformatics, the UVC algorithm demonstrated superior accuracy in detecting somatic variants crucial for cancer diagnosis and treatment. Key findings indicate its effectiveness across various NGS scenarios, achieving 100% concordance in a study involving colon adenoma patients. Genetron plans to leverage these insights to improve test sensitivity and precision.
Genetron Holdings Limited (NASDAQ: GTH) has announced a strategic partnership with NeoGenomics, Inc. (NASDAQ: NEO) to enhance global oncology drug development. This collaboration aims to synchronize clinical trials and diagnostics across China and globally, leveraging their combined expertise and infrastructure. Both companies will streamline drug trials and diagnostic development, integrating their advanced technological capabilities. This partnership is expected to accelerate market approval for new oncology treatments, benefiting patients worldwide.
Genetron Holdings Limited (NASDAQ: GTH) announced it will release its unaudited financial results for Q3 2021 on November 30, 2021, prior to the US market opening. The company specializes in precision oncology, including molecular profiling tests and early cancer screening. A conference call is scheduled for 8:30 a.m. ET on the same day, with access details provided. Genetron Health aims to enhance cancer treatment through advanced technologies and partnerships with biopharmaceutical companies.
Genetron Holdings Limited (Nasdaq: GTH) announced that its Onco PanScan™ product received the CE mark, allowing for marketing in the European Union. This genomic profiling test covers over 800 genes, aiding personalized cancer treatment and targeted therapy. The CE mark signifies compliance with EU standards, crucial for market access. Genetron also holds approvals for other assays in China and is preparing for an IVD registrational trial. CEO Sizhen Wang emphasized the company’s growth across various business lines in molecular diagnostics.
Genetron Holdings Limited (Nasdaq: GTH) announced significant recognition for its HCCscreen™ liver cancer screening product in the Chinese Journal of Hepatology. Clinical results from Genetron's HIT study indicated better performance than traditional methods, receiving endorsements from leading experts in hepatology and oncology. Two influential articles underscored HCCscreen™'s diagnostic value, emphasizing its potential for early detection of hepatocellular carcinoma (HCC). CEO Sizhen Wang highlighted the company's commitment to advancing early screening initiatives in China.
Genetron Holdings Limited (NASDAQ: GTH) has partnered with Jiangsu Fosun Pharmaceutical Sales Co., Ltd. to launch Seq-MRD®, a diagnostic tool for detecting minimal residual disease in hematologic cancer patients in China. This collaboration aims to promote Seq-MRD® in hematologic-focused hospitals, leveraging Fosun's experienced sales force of about 1,500 representatives. The Seq-MRD® assay, optimized with Genetron's One-step Seq technology, promises high accuracy, cost-efficiency, and fast turnaround times. The hematologic cancer market in China presents significant potential, with an estimated 135,000 new patients diagnosed in 2017.
FAQ
What is the market cap of Genetron Holdings (GTH)?
What does Genetron Holdings Limited specialize in?
What are some of Genetron's key products?
What recent corporate action has Genetron announced?
What is HCCscreen?
What is the significance of Genetron's merger?
What happens to Genetron's ADSs after the merger?
Who are the major stakeholders involved in the merger?
When is the merger expected to complete?
What services does Genetron offer in genomics research?
Where can I find more information about Genetron's financial filings?
